Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.43 |
| ▸ | NPC1 | O15118 | 11/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.43 |
| ▸ | MAPT | P10636 | 7/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 5/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.43 |
| ▸ | TP53 | P04637 | 2/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | PPARG | P37231 | 1/20 | 0.43 |
| ▸ | NCOA2 | Q15596 | 1/20 | 0.43 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.43 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.43 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 4/20 | 0.41 |
| ▸ | MEN1 | O00255 | 4/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7410420 | 0.77 | RAB9A (0.48) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL706413 | 0.75 | ILK (0.46) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL7902646 | 0.75 | RAB9A (0.40) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL5323085 | 0.70 | RAB9A (0.49) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL29117998 | 0.70 | RAB9A (0.46) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL827403 | 0.70 | RAB9A (0.67) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| SCHEMBL547704 | 0.69 | NPC1 (0.45) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| Hydrogen Sulfide SCHEMBL16859912 | 0.68 | RAB9A (0.64) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| Hydrogen Sulfide SCHEMBL28205214 | 0.68 | RAB9A (0.64) | RAB9ANPC1KDM4EMAPTALDH1A1 | |
| Methane SCHEMBL28056221 | 0.68 | RAB9A (0.64) | RAB9ANPC1KDM4EMAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2735562-B2 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2023-11-15 | — | — | EP | disclosed |
| EP-2735562-B1 | Estrogen receptor modulators and uses thereof | SERAGON PHARMACEUTICALS INC (US) | 2015-03-11 | — | — | EP | disclosed |
| EP-2735562-A1 | Estrogen receptor modulators and uses thereof | Seragon Pharmaceuticals, Inc. (US) | 2014-05-28 | — | — | EP | disclosed |
| WO-2014070988-A1 | COMPOUNDS AND METHODS TO ENHANCE THE ORAL AVAILABILITY OF GLYCOMIMETICS | GLYCOMIMETICS, INC. (US) | 2014-05-08 | — | — | WO | disclosed |
| US-8524675-B2 | Antibacterial aminoglycoside analogs | ACHAOGEN, INC. (US) | 2013-09-03 | — | — | US | disclosed |
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | ACHAOGEN, INC. (US) | 2012-06-28 | — | — | US | disclosed |
| US-4782158-A | CEPHEM ANTIBIOTIC INTERMEDIATES | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1988-11-01 | — | — | US | disclosed |
| US-4599426-A | INTERMEDIATES FOR CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO. (JP) | 1986-07-08 | — | — | US | disclosed |
| US-4506076-A | MICROBIOCIDES, CEPHALOSPORINS | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-03-19 | — | — | US | disclosed |
| EP-0009548-B1 | CEPHALOSPORIN DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1985-01-16 | — | — | EP | disclosed |
| EP-0059486-A1 | New starting compounds for preparing cephem compounds and processes for their preparation | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1982-09-08 | — | — | EP | disclosed |
| US-4288435-A | 3,7-Disubstituted-3-cephem-4-carboxylic acid compounds and pharmaceutical antibacterial compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1981-09-08 | — | — | US | disclosed |
| EP-0009548-A2 | Cephalosporin derivatives, process for their preparation and pharmaceutical compositions containing them | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1980-04-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120165282-A1 | ANTIBACTERIAL AMINOGLYCOSIDE ANALOGS | MRPL21, QARS1, NQO2 | RAB9A 424/4885NPC1 653/4885KDM4E 4047/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.